May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Anterior Juxtascleral Depot of Anecortave Acetate: Intraocular Pressure Reduction in Different Types of Glaucoma
Author Affiliations & Notes
  • T. S. Prata
    Ophthalmology, Federal University of Sao Paulo / UNIFESP-EPM, Sao Paulo, Brazil
  • I. M. Tavares
    Ophthalmology, Federal University of Sao Paulo / UNIFESP-EPM, Sao Paulo, Brazil
  • P. A. A. Mello
    Ophthalmology, Federal University of Sao Paulo / UNIFESP-EPM, Sao Paulo, Brazil
  • C. Y. Tamura
    Ophthalmology, Federal University of Sao Paulo / UNIFESP-EPM, Sao Paulo, Brazil
  • R. Belfort, Jr.
    Ophthalmology, Federal University of Sao Paulo / UNIFESP-EPM, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships  T.S. Prata, None; I.M. Tavares, None; P.A.A. Mello, None; C.Y. Tamura, None; R. Belfort, C, C.
  • Footnotes
    Support  Alcon
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1205. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. S. Prata, I. M. Tavares, P. A. A. Mello, C. Y. Tamura, R. Belfort, Jr.; Anterior Juxtascleral Depot of Anecortave Acetate: Intraocular Pressure Reduction in Different Types of Glaucoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1205. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy and safety of anecortave acetate (AA) anterior juxtascleral depot (AJD) injection to reduce intraocular pressure (IOP) in glaucoma patients.

Methods: : We conducted a prospective, non-randomized open-labeled clinical trial in 25 eyes of 25 uncontrolled glaucoma patients. All received a single AJD of AA (30 mg) in the selected eye under topical anesthesia. IOP was measured and adverse events were assessed at week 1, 1 month and 3 months.

Results: : Mean age was 60 (+/- 17) years. Most of the patients presented primary open angle glaucoma (8 - 32%) or uveitic / steroid induced glaucoma (9 - 36%). Regarding gonioscopy, 48% of the patients had an open angle, 12% < 90° of angle closure, and 40% >90° of angle closure. Mean IOP at baseline was 30.9 (+/- 9.2) mmHg and 53.5% of the patients had prior intraocular surgery. Mean IOP at the first three months were 20.9 (+/-7.5) mmHg, 21.5 (+/-7.6) mmHg and 19.1 (+/- 5.2) mmHg, respectively. Mean IOP reduction of 33.3%, 31.7% and 38.3% were observed at the first, second and third month, respectively. At month 3, angle closure glaucoma eyes had a mean IOP of 17.4 mmHg (reduction of 43.7%) while open angle glaucoma eyes had a mean IOP of 20.7 (reduction of 32.9%). A mild subconjunctival hemorrhage was observed in four cases. One eye developed a small and transient corneal dellen at the first week.

Conclusions: : AA administered as an AJD presented a significant IOP reduction for at least three months with no clinically apparent serious adverse events in eyes with different types of glaucoma.

Clinical Trial: : www.clinicaltrials.gov NCT0053962

Keywords: intraocular pressure • injection • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×